2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-114618
    S33084 273203-30-8 98%
    S33084 is a dopamine D(3)-receptor antagonist with the pKi values of 8.72, 8.62 and 6.82 of cloned rat dopamine D3 receptor, native rat dopamine D3 and D2 receptor.
    S33084
  • HY-114659
    AM-36 199467-52-2 98%
    AM-36 is a neuroprotective agent with combined antioxidant and sodium channel blocking actions. AM-36 can inhibit cell apoptosis and ROS prodiction. AM-36 can reduce neuronal damage and DA release after middle cerebral artery occlusion in rats. AM-36 can be used for the researches of inflammation and neurological disease, such as stroke.
    AM-36
  • HY-114678
    LY302148 182564-47-2 98%
    LY302148 is a receptor ligand for 5-HT1F. Compared to the Emax of 5-HT, LY302148 behaves as a partial agonist for the 5-HT1F receptor. In the [35S]GTPγS binding assay targeting human 5-HT1F receptors, LY302148 exhibits good potency with an EC50 value of 5.23 nM. LY302148 can be used in the research of migraine.
    LY302148
  • HY-114692
    Eterobarb 27511-99-5 98%
    Eterobarb (EX 12-095), a barbiturate derivative, is an anticonvulsant agent.
    Eterobarb
  • HY-114705
    Ameltolide 787-93-9
    Ameltolide (LY-201116; ADD 75073) is a novel anticonvulsant agent and can be used for epilepsy research.
    Ameltolide
  • HY-114791
    Lobelanidine 552-72-7 98%
    Lobelanidine is an antagonist for nicotinic acetylcholine receptor (nAChR), which inhibits α7 nAChR response and α3β2/α3β4 nAChR responses, with IC50 of 2.8 and 8.2 μM.
    Lobelanidine
  • HY-114798
    Rabelomycin 28399-50-0 98%
    Rabelomycin is antibiotic, which exhibits antimicrobial activity against gram positive bacteria. Rabelomycin exhibits inhibitory activity against inducible nitric oxide synthase (iNOS) with an IC50 of 63.9 μM.
    Rabelomycin
  • HY-114880
    AB-FUBINACA 3-fluorobenzyl isomer 1185282-19-2 98%
    AB-FUBINACA 3-fluorobenzyl isomer is a synthetic cannabinoid that belongs to the indole derivatives and has a high affinity for the central CB1 receptors (Ki= 0.9 nM), exhibiting anticonvulsant activity.
    AB-FUBINACA 3-fluorobenzyl isomer
  • HY-114883
    Homocarnosine 3650-73-5 98%
    Homocarnosine is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects.Homocarnosine has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation.
    Homocarnosine
  • HY-114884
    RS-0406 530112-00-6 98%
    RS-0406 is a beta-sheet breaker targeting Amyloid-β. RS-0406 can inhibits Aβ(1-42) fibrillogenesis and protect against Aβ(1-42)-induced cytotoxicity in primary hippocampal neurons. RS-0406 can be used for the research of neurological disease, such as Alzheimer's disease (AD).
    RS-0406
  • HY-114895
    SSR504734 free base 742693-38-5 98%
    SSR504734 free base is an orally active, selective and reversible inhibitor of human, rat, and mouse GlyT1 (IC50=18, 15, and 38 nM, respectively). SSR504734 free base shows anti-schizophrenia, anti-anxiety and anti-depression activities.
    SSR504734 free base
  • HY-114898
    ML404 1826026-00-9 98%
    ML404 (Compound 38) is an inhibitor of the mitochondrial permeability transition pore (mtPTP), which can suppress mitochondrial swelling (EC50=4.9 nM) and only disrupts mitochondrial coupling (an adverse effect) at concentrations > 100 μM. ML404 can be utilized in research related to multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MD), myocardial infarction, and stroke.
    ML404
  • HY-114899
    Azamethiphos 35575-96-3
    Azamethiphos is an organophosphate insecticide that inhibits AChE. Azamethiphos inhibits sea lice.
    Azamethiphos
  • HY-114901
    A-134974 186141-75-3 98%
    A-134974 is a novel, high-selectivity adenosine kinase (IC50 = 60 pM) inhibitor. A-134974 enhances endogenous adenosine signaling in the spinal cord, effectively alleviates neuropathic pain, and does not cause movement disorders. A-134974 can be used for the study of neuropathic pain.
    A-134974
  • HY-114915
    PSB-1434 1619884-65-9 98.05%
    PSB-1434 is a selective monoamine oxidase B (MAO-B) inhibitor with an IC50 of 1.59 nM. PSB-1434 shows >6000-fold selective for MAO-B than MAO-A.
    PSB-1434
  • HY-114945
    CGRP antagonist 2 866086-05-7 98%
    CGRP antagonist 2 is a CGRP receptor antagonist. CGRP antagonist 2 can be used for pain relief.
    CGRP antagonist 2
  • HY-114946
    N-methyl-4,4-difluoro Modafinil 1613222-54-0 98%
    N-methyl-4,4-difluoro Modafinil is categorized as a nootropic.
    N-methyl-4,4-difluoro Modafinil
  • HY-114954
    CID1792197 1164479-69-9 98%
    CID1792197 is a GPR55 agonist with an EC50 value of 0.11 μM.
    CID1792197
  • HY-114975
    EGIS-8332 220725-87-1 98%
    EGIS-8332 is a non-competitive AMPA receptor antagonist. EGIS-8332 inhibits AMPA currents in rat cerebellar Purkinje cells and inhibited the AMPA- and Quisqualate-induced excitotoxicity in primary cultures of telencephalon neurons (IC50 = 5.1-9.0 μM). EGIS-8332 exhibits anticonvulsant and neuroprotective effects. EGIS-8332 can be used for the research of neurological disease.
    EGIS-8332
  • HY-114987
    EMD 21657 61711-37-3 98%
    EMD 21657 is a derivative of Piracetam (HY-B0585). EMD 21657 inhibits LOT compound action potential, and enhances the local anesthetic effect of Hexanol (HY-W032022). EMD 21657 exhibits hemolytic effect, and can be used in research about alcoholic encephalopathy syndrome.
    EMD 21657
Cat. No. Product Name / Synonyms Application Reactivity